Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947716 | 1.00 | KDM4E (0.56) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL13605071 | 1.00 | KDM4E (0.56) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29799941 | 0.98 | KDM4E (0.54) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30839329 | 0.97 | KDM4E (0.53) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30148431 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30305304 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29732484 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30305288 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30305639 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29800140 | 0.96 | KDM4E (0.52) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4308114-B1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE FARM SPA (IT) | 2026-02-11 | — | — | EP | claimed |
| EP-4646203-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2025-11-12 | — | — | EP | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025123056-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2024204250-A1 | DOPAMINE RELEASE AMOUNT ENHANCING AGENT, EXERCISE CONTROL FUNCTION IMPROVING AGENT, EXERCISE LEARNING FUNCTION IMPROVING AGENT, AND ACTIVITY MOTIVATION IMPROVING AGENT | 株式会社明治 | 2024-10-03 | — | — | WO | claimed |
| WO-2024177909-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT IN SUBJECTS HAVING A FIBROTIC DISEASE USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| WO-2022195017-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-22 | — | — | WO | claimed |
| EP-4059497-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompé farmaceutici S.p.a. (IT) | 2022-09-21 | — | — | EP | claimed |
| CN-114644734-A | Glycopeptide-enriched polymer material, preparation and application | 中国科学院大连化学物理研究所 | 2022-06-21 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2007016431-A2 | NOVEL BENZO [D] [1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | KDM4E 4402/4885MEN1 1465/4885LMNA 4574/4885 |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | KDM4E 1030/4885MEN1 1261/4885LMNA 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.